Search Results - "Overman, M J"

Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H) by Goldstein, J., Tran, B., Ensor, J., Gibbs, P., Wong, H.L., Wong, S.F., Vilar, E., Tie, J., Broaddus, R., Kopetz, S., Desai, J., Overman, M.J.

“…The microsatellite instability-high (MSI-H) phenotype, present in 15% of early colorectal cancer (CRC), confers good prognosis. MSI-H metastatic CRC is rare…”
Get full text

Association between KRAS mutation and lung metastasis in advanced colorectal cancer by Pereira, A A L, Rego, J F M, Morris, V, Overman, M J, Eng, C, Garrett, C R, Boutin, A T, Ferrarotto, R, Lee, M, Jiang, Z-Q, Hoff, P M, Vauthey, J-N, Vilar, E, Maru, D, Kopetz, S

“…Background: KRAS mutations have been associated with lung metastases at diagnosis of metastatic colorectal cancer (mCRC), but the impact of this mutation on…”
Get full text

Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix by Lieu, C.H., Lambert, L.A., Wolff, R.A., Eng, C., Zhang, N., Wen, S., Rafeeq, S., Taggart, M., Fournier, K., Royal, R., Mansfield, P., Overman, M.J.

“…Poorly differentiated and signet ring cell adenocarcinomas of the appendix represent a subset with aggressive tumor biology and poor outcomes with few studies…”
Get full text

Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer by Morris, V.K., Lucas, F. A. San, Overman, M.J., Eng, C., Morelli, M.P., Jiang, Z.-Q., Luthra, R., Meric-Bernstam, F., Maru, D., Scheet, P., Kopetz, S., Vilar, E.

“…KRAS mutations in codons 12 and 13 are present in ∼40% of all colorectal cancers (CRC). Activating mutations in codons 61 and 146 of KRAS and in codons 12, 13,…”
Get full text

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response by Liu, X, George, G C, Tsimberidou, A M, Naing, A, Wheler, J J, Kopetz, S, Fu, S, Piha-Paul, S A, Eng, C, Falchook, G S, Janku, F, Garrett, C, Karp, D, Kurzrock, R, Zinner, R, Raghav, K, Subbiah, V, Hess, K, Meric-Bernstam, F, Hong, D S, Overman, M J

“…This retrospective study aims to investigate the activity of retreatment with anti-EGFR-based therapies in order to explore the concept of clonal evolution by…”
Get full text

A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy by Jiang, Z.-Q., Varadhachary, G., Wang, X., Kopetz, S., Lee, J.E., Wang, H., Shroff, R., Katz, M., Wolff, R.A., Fleming, J., Overman, M.J.

“…Whether carcinomas of the ampulla of Vater should be classified with biliary tract tumors and treated in a similar manner remains unknown. We sought to compare…”
Get full text

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 by André, T., Lonardi, S., Wong, K.Y.M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M.A., Van Cutsem, E., McDermott, R., Hill, A., Sawyer, M.B., Hendlisz, A., Neyns, B., Abdullaev, S., Memaj, A., Lei, M., Dixon, M., Kopetz, S., Overman, M.J.

“…In the phase II multicohort CheckMate 142 study, nivolumab plus low-dose (1 mg/kg) ipilimumab provided robust and durable clinical benefit with a manageable…”
Get full text

High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients by Allenson, K, Castillo, J, San Lucas, F A, Scelo, G, Kim, D U, Bernard, V, Davis, G, Kumar, T, Katz, M, Overman, M J, Foretova, L, Fabianova, E, Holcatova, I, Janout, V, Meric-Bernstam, F, Gascoyne, P, Wistuba, I, Varadhachary, G, Brennan, P, Hanash, S, Li, D, Maitra, A, Alvarez, H

“…Exosomes arise from viable cancer cells and may reflect a different biology than circulating cell-free DNA (cfDNA) shed from dying tissues. We compare…”
Get full text

JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions by Yoshino, T., Pentheroudakis, G., Mishima, S., Overman, M.J., Yeh, K.-H., Baba, E., Naito, Y., Calvo, F., Saxena, A., Chen, L.-T., Takeda, M., Cervantes, A., Taniguchi, H., Yoshida, K., Kodera, Y., Kitagawa, Y., Tabernero, J., Burris, H., Douillard, J.-Y.

“…A Japan Society of Clinical Oncology (JSCO)-hosted expert meeting was held in Japan on 27 October 2019, which comprised experts from the JSCO, the Japanese…”
Get full text

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge by Parseghian, C.M., Loree, J.M., Morris, V.K., Liu, X., Clifton, K.K., Napolitano, S., Henry, J.T., Pereira, A.A., Vilar, E., Johnson, B., Kee, B., Raghav, K., Dasari, A., Wu, J., Garg, N., Raymond, V.M., Banks, K.C., Talasaz, A.A., Lanman, R.B., Strickler, J.H., Hong, D.S., Corcoran, R.B., Overman, M.J., Kopetz, S.

“…Colorectal cancer (CRC) has been shown to acquire RAS and EGFR ectodomain mutations as mechanisms of resistance to epidermal growth factor receptor (EGFR)…”
Get full text

Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment by Morelli, M.P., Overman, M.J., Dasari, A., Kazmi, S.M.A., Mazard, T., Vilar, E., Morris, V.K., Lee, M.S., Herron, D., Eng, C., Morris, J., Kee, B.K., Janku, F., Deaton, F.L., Garrett, C., Maru, D., Diehl, F., Angenendt, P., Kopetz, S.

“…Colorectal tumors become more heterogeneous after progression on EGFR-inhibitors by developing multiple independent mutations. Upon discontinuation of…”
Get full text

Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations by Passot, Guillaume, MD, PhD, Chun, Yun S., MD, FACS, Kopetz, Scott E., MD, Overman, Michael J., MD, Conrad, Claudius, MD, PhD, Aloia, Thomas A., MD, FACS, Vauthey, Jean-Nicolas, MD, FACS

“…Abstract Background After resection of colorectal liver metastases (CLM), RAS mutations are associated with modest survival benefit and second-line…”
Get full text

The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma by Overman, M.J., Feng, L., Pro, B., McLaughlin, P., Hess, M., Samaniego, F., Younes, A., Romaguera, J.E., Hagemeister, F.B., Kwak, L., Cabanillas, F., Rodriguez, M.A., Fayad, L.E.

“…The benefit of adding rituximab to anthracycline-based therapy for follicular lymphoma grade 3 has not been studied. We retrospectively reviewed the records of…”
Get full text

Defining the subset of mutations in polymerase epsilon (POLE) associated with loss-of-proofreading (LOP) functionality by Maddalena, G, Zeineddine, F A, Rivero-Hinojosa, S, Aushev, V N, Chowdhury, S, Zeineddine, M A, Yousef, A M, Yap, T A, EINaggar, A C, Liu, M C, White, M, Overman, M J, Kopetz, S, Shen, J P

Get more information

On the underreporting of health-related quality of life and regulatory approval by Bhamidipati, D., Anand, S., Gothwal, A., Raghav, K., Overman, M.J.

Get full text

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer by Overman, M.J., Adam, L., Raghav, K., Wang, J., Kee, B., Fogelman, D., Eng, C., Vilar, E., Shroff, R., Dasari, A., Wolff, R., Morris, J., Karunasena, E., Pisanic, R., Azad, N., Kopetz, S.

“…Hypermethylation of promoter CpG islands [CpG island methylator phenotype (CIMP)] represents a unique pathway for the development of colorectal cancer (CRC),…”
Get full text

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer by Ambrosini, M, Rousseau, B, Manca, P, Artz, O, Marabelle, A, André, T, Maddalena, G, Mazzoli, G, Intini, R, Cohen, R, Cercek, A, Segal, N H, Saltz, L, Varghese, A M, Yaeger, R, Nusrat, M, Goldberg, Z, Ku, G Y, El Dika, I, Margalit, O, Grinshpun, A, Murtaza Kasi, P, Schilsky, R, Lutfi, A, Shacham-Shmueli, E, Khan Afghan, M, Weiss, L, Westphalen, C B, Conca, V, Decker, B, Randon, G, Elez, E, Fakih, M, Schrock, A B, Cremolini, C, Jayachandran, P, Overman, M J, Lonardi, S, Pietrantonio, F

“…POLE and POLD1 proofreading deficiency (POLE/D1pd) define a rare subtype of ultramutated metastatic colorectal cancer (mCRC; over 100 mut/Mb). Disease-specific…”
Get more information

Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma by Schueneman, A, Goggins, M, Ensor, J, Saka, B, Neishaboori, N, Lee, S, Maitra, A, Varadhachary, G, Rezaee, N, Wolfgang, C, Adsay, V, Wang, H, Overman, M J

“…Background: Outcomes for ampullary adenocarcinomas are heterogeneous, and numerous methods of categorisation exist. A histomolecular phenotype based on…”
Get full text

Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine by Overman, M J, Pozadzides, J, Kopetz, S, Wen, S, Abbruzzese, J L, Wolff, R A, Wang, H

“…Background: Despite having a dramatically larger surface area than the large intestine, the small intestine is an infrequent site for the development of…”
Get full text

Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms by Choe, J. H., Overman, M. J., Fournier, K. F., Royal, R. E., Ohinata, A., Rafeeq, S., Beaty, K., Phillips, J. K., Wolff, R. A., Mansfield, P. F., Eng, C.

“…Background Currently, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are accepted treatments for surgically resectable appendiceal…”
Get full text